ES2563751T3 - Uso de 4-aminopiridina sostenida de liberación para mejorar el deterioro neuro-cognitivo y / o neuro-psiquiátrico de los pacientes con esclerosis múltiple (EM) - Google Patents

Uso de 4-aminopiridina sostenida de liberación para mejorar el deterioro neuro-cognitivo y / o neuro-psiquiátrico de los pacientes con esclerosis múltiple (EM) Download PDF

Info

Publication number
ES2563751T3
ES2563751T3 ES10808713.1T ES10808713T ES2563751T3 ES 2563751 T3 ES2563751 T3 ES 2563751T3 ES 10808713 T ES10808713 T ES 10808713T ES 2563751 T3 ES2563751 T3 ES 2563751T3
Authority
ES
Spain
Prior art keywords
aminopyridine
cminss
therapeutically effective
effective amount
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES10808713.1T
Other languages
English (en)
Spanish (es)
Inventor
Thomas C. Wessel
Andrew Blight
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Acorda Therapeutics Inc
Original Assignee
Acorda Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acorda Therapeutics Inc filed Critical Acorda Therapeutics Inc
Application granted granted Critical
Publication of ES2563751T3 publication Critical patent/ES2563751T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
ES10808713.1T 2009-08-11 2010-08-11 Uso de 4-aminopiridina sostenida de liberación para mejorar el deterioro neuro-cognitivo y / o neuro-psiquiátrico de los pacientes con esclerosis múltiple (EM) Active ES2563751T3 (es)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US23307709P 2009-08-11 2009-08-11
US23306909P 2009-08-11 2009-08-11
US233069P 2009-08-11
US233077P 2009-08-11
US23987709P 2009-09-04 2009-09-04
US239877P 2009-09-04
PCT/US2010/045211 WO2011019845A1 (en) 2009-08-11 2010-08-11 Use of 4-aminopyridine to improve neuro-cognitive and/or neuro-psychiatric impairment in patients with demyelinating and other nervous system conditions

Publications (1)

Publication Number Publication Date
ES2563751T3 true ES2563751T3 (es) 2016-03-16

Family

ID=43586462

Family Applications (1)

Application Number Title Priority Date Filing Date
ES10808713.1T Active ES2563751T3 (es) 2009-08-11 2010-08-11 Uso de 4-aminopiridina sostenida de liberación para mejorar el deterioro neuro-cognitivo y / o neuro-psiquiátrico de los pacientes con esclerosis múltiple (EM)

Country Status (17)

Country Link
US (8) US20130053420A1 (OSRAM)
EP (1) EP2464229B1 (OSRAM)
JP (2) JP6137833B2 (OSRAM)
KR (2) KR20120050473A (OSRAM)
CN (1) CN102143687B (OSRAM)
AR (1) AR077858A1 (OSRAM)
AU (1) AU2010282509B2 (OSRAM)
BR (1) BRPI1003991A2 (OSRAM)
CA (1) CA2770698C (OSRAM)
ES (1) ES2563751T3 (OSRAM)
JO (1) JO3348B1 (OSRAM)
MX (1) MX2012001814A (OSRAM)
RU (1) RU2563821C2 (OSRAM)
TW (2) TW201613585A (OSRAM)
UY (1) UY32837A (OSRAM)
WO (1) WO2011019845A1 (OSRAM)
ZA (1) ZA201201001B (OSRAM)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8007826B2 (en) 2003-12-11 2011-08-30 Acorda Therapeutics, Inc. Sustained release aminopyridine composition
US8354437B2 (en) 2004-04-09 2013-01-15 Acorda Therapeutics, Inc. Method of using sustained release aminopyridine compositions
WO2012009204A1 (en) * 2010-07-15 2012-01-19 The Trustees Of Columbia University In The City Of New York Methods for diagnosing and treating concussive disorders
EP2667869A1 (en) * 2011-01-28 2013-12-04 Acorda Therapeutics, Inc. Use of potassium channel blockers to treat cerebral palsy
CA2840591A1 (en) 2011-06-30 2013-01-03 Biomarin Pharmaceuticals, Inc. Methods of administering 3,4-diaminopyridine
US10905663B2 (en) 2013-03-05 2021-02-02 The University Of Chicago Treatment of demyelinating disorders
WO2014172266A1 (en) * 2013-04-15 2014-10-23 Acorda Therapeutics, Inc. Methods for treating sensorimotor impairments associated with certain types of stroke using aminopyridines
DE102014221687B4 (de) * 2014-10-24 2019-07-04 Danfoss Silicon Power Gmbh Leistungshalbleitermodul mit kurzschluss-ausfallmodus
DE102017115701B4 (de) * 2017-07-12 2022-03-03 Lts Lohmann Therapie-Systeme Ag Fampridin-TTS

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE82916B1 (en) * 1990-11-02 2003-06-11 Elan Corp Plc Formulations and their use in the treatment of neurological diseases
US5977131A (en) 1997-04-09 1999-11-02 Pfizer Inc. Azaindole-ethylamine derivatives as nicotinic acetylcholine receptor binding agents
AU2002250307A1 (en) * 2001-03-14 2002-09-24 The Government Of The United States Of America, As Represented By The Secretary Of Health And Human Improving postsynaptic response by a combination of 4-minopyridine and agonist
US8007826B2 (en) * 2003-12-11 2011-08-30 Acorda Therapeutics, Inc. Sustained release aminopyridine composition
US8354437B2 (en) * 2004-04-09 2013-01-15 Acorda Therapeutics, Inc. Method of using sustained release aminopyridine compositions

Also Published As

Publication number Publication date
US20160213661A1 (en) 2016-07-28
CN102143687B (zh) 2015-11-25
MX2012001814A (es) 2012-06-01
WO2011019845A1 (en) 2011-02-17
UY32837A (es) 2011-03-31
US20190247379A1 (en) 2019-08-15
CN102143687A (zh) 2011-08-03
RU2012108656A (ru) 2013-09-20
HK1173911A1 (zh) 2013-05-31
US20170281608A1 (en) 2017-10-05
US20170056385A1 (en) 2017-03-02
AU2010282509B2 (en) 2015-07-30
CA2770698C (en) 2018-01-30
US20130053420A1 (en) 2013-02-28
US20190015399A1 (en) 2019-01-17
KR20120050473A (ko) 2012-05-18
US20200113882A1 (en) 2020-04-16
AU2010282509A1 (en) 2012-03-01
EP2464229B1 (en) 2015-11-25
TW201110967A (en) 2011-04-01
JP2016074728A (ja) 2016-05-12
EP2464229A1 (en) 2012-06-20
ZA201201001B (en) 2014-10-29
KR20170128633A (ko) 2017-11-22
TWI549678B (zh) 2016-09-21
RU2563821C2 (ru) 2015-09-20
JP2013501805A (ja) 2013-01-17
JP6137833B2 (ja) 2017-05-31
EP2464229A4 (en) 2013-02-13
BRPI1003991A2 (pt) 2015-09-15
US20180147193A1 (en) 2018-05-31
TW201613585A (en) 2016-04-16
JO3348B1 (ar) 2019-03-13
CA2770698A1 (en) 2011-02-17
AR077858A1 (es) 2011-09-28

Similar Documents

Publication Publication Date Title
ES2563751T3 (es) Uso de 4-aminopiridina sostenida de liberación para mejorar el deterioro neuro-cognitivo y / o neuro-psiquiátrico de los pacientes con esclerosis múltiple (EM)
Walter-Sack et al. High absolute bioavailability of methylene blue given as an aqueous oral formulation
ES2307975T3 (es) Composiciones analgesicas que comprenden antagonistas del receptor de nmda y cloruro de benzalconio.
ES2760251T3 (es) Método para el tratamiento de trastorno de estrés postraumático
US9585893B2 (en) Flumazenil complexes, compositions comprising same and uses thereof
ES2474945T3 (es) Soluciones farmacéuticas, procedimiento de preparación y usos terapéuticos
ES2302742T5 (es) Pulverizador nasal para suministrar una composición farmacéutica.
RU2769397C2 (ru) Композиции и способы лечения передозировки опиоидами
ES2979034T3 (es) Procedimientos de tratamiento del síndrome de Lennox-Gastaut mediante el uso de fenfluramina
ES2631504B1 (es) Medicamentos de administración nasal y métodos para su uso
ES2843952T3 (es) Composiciones para tratar el insomnio
ES2691309T3 (es) Soluciones orales estables para API combinados
US20180169006A1 (en) Co-packaged drug products
BRPI0715433A2 (pt) soluÇÕes concentradas de metotrexato
CA2536582A1 (en) Intranasal opioid compositions
ES2738678T3 (es) Orvepitant para el tratamiento de la tos crónica
WO2018064672A1 (en) Treatment with intranasal naloxone
ES2886873T3 (es) Composiciones farmacéuticas para mejorar el rendimiento de la memoria
TWI323660B (en) Pten inhibitor or maxi-k channels opener
WO2002056964A1 (es) Empleo de flumazenilo en la elaboración de una medicación para el tratamiento de la dependencia de alcohol
JP2024506861A (ja) 物質使用障害の治療のための隔離化合物及びその使用
CN101678010B (zh) 包含(R)-螺[1-氮杂二环[2.2.2]辛烷-3,2’(3’H)-呋喃并[2,3-b]吡啶](AZD0328)的组合物及其在制备治疗阿耳茨海默氏病、ADHD和认知功能障碍的药物中的用途
EP4590277A1 (en) Pharmaceutical compositions
KR20120030542A (ko) 리팍시민에 대한 전신 노출의 조절
JP7627353B2 (ja) チザニジン液体製剤及びその用途